5:10 PM
 | 
Apr 29, 2010
 |  BC Extra  |  Company News

EC approves Tarceva for first-line NSCLC

The EC approved an MAA from Roche (SIX:ROG; OTCQX:RHHBY) for Tarceva erlotinib for first-line maintenance treatment of advanced non-small cell lung cancer (NSCLC) in patients with...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >